Jason Zemansky, an analyst from Bank of America Securities, reiterated the Buy rating on Insmed. The associated price target remains the same with $142.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jason Zemansky has given his Buy rating due to a combination of factors that highlight Insmed’s potential for growth. The recent success of United’s TETON-2 trial, which evaluated Tyvaso for idiopathic pulmonary fibrosis (IPF), has opened a significant market opportunity for Insmed’s treprostinil prodrug, TPIP. This success suggests a potential $4 billion market, with TPIP poised to capture a substantial share due to its advantages such as once-daily administration and fewer side effects compared to native treprostinil.
Despite some uncertainties regarding the full clinical picture and the timing of pivotal trials, Zemansky remains optimistic about Insmed’s prospects. The company is expected to provide further guidance, and with upcoming meetings with the FDA, there is hope for an accelerated path forward. Additionally, Insmed’s commercial potential in non-cystic fibrosis bronchiectasis (NCFB) and other upcoming catalysts contribute to the positive outlook, reinforcing the Buy rating with a price objective of $142.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $145.00 price target.